Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The firm’s product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. Its product candidate, Selonabant, is a small molecule antagonist of cannabinoid binding receptor type-1. The company was founded by Joseph F. Lawler on April 23, 2020 and is headquartered in Lakeway, TX.

Agrify

Clever Leaves Holdings Inc

Greenlane Holdings

Hydrofarm Holdings Group

Jazz Pharmaceuticals

Akerna Corp

Merida Merger

Scotts Miracle-Gro

Turning Point Brands

Urban-gro

Village Farms International

cbdMD Inc

Zynerba Pharmaceuticals

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

A Week's Worth of Actionable Cannabis Stock News

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced the formation of a Scientific Advisory Board (SAB) to advise on the Company's clinical development programs and its product pipeline. The founding co-chairs are Andrew Monte, M.D., Ph.D. and Arjun Chanmugam, M.D., both recog

Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members

Cannabinoid-focused biotech company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) released its third-quarter fiscal 2021 financial results on Tuesday with a net loss of $555,832 or $0.04 per share.  The Austin, Texas-based company had its initial public offering in May with 2.08 million shares, priced at $7.00 per share.

Cannabinoid-Focused Anebulo Pharma Posts Q3 Earnings, On Schedule To Start Cannabis Overdose Clinical Trials

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid intoxication and substance addiction, today reported recent business highlights and announced financial results for the fiscal year 2021 third quarter, ended March 31, 2021. Business highlights for the quarter and recent weeks include the following: Completed an initial public offering (

Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results

Five Star Bancorp

Bowman Consulting Group

Honest Co

Maquia Capital Acquisition Corp

Onion Global Ltd

Talaris Therapeutics

Gyroscope Therapeutics Holdings

Waterdrop

Eight IPOs and four SPACs went public this past week. The week's best performer, Sacramento bank Five Star Bancorp (FSBC) priced at the high end to raise $105 million at a $325 million market cap.

U.S. IPO Weekly Recap: Sacramento Bank Five Star Bancorp Finishes On Top In An 8 IPO Week

Waterdrop, Talaris Therapeutics, Anebulo Pharmaceuticals and Bowman Consulting Group are making their public equities market debuts on Friday.

4 Companies Open for Trading

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction, today announced the pricing of its initial public offering of 3,000,000 shares of common stock at a public offering price of $7.00 per share. The gross proceeds from the offering to the Company, before deducting underwriting discounts and commissions and

Anebulo Pharmaceuticals Announces Pricing of Initial Public Offering

News for Anebulo Pharmaceuticals Stock (ANEB)